SPIRE2: A Potential Drug Target and Biomarker (G84501)
SPIRE2: A Potential Drug Target and Biomarker
SPIRE2, or Spire Family Actin Nucleation Factor 2, is a protein that plays a crucial role in the development and maintenance of tissues and organs, including blood vessels, neurons, and heart muscle. It is a key regulator of actin dynamics and cell-cell adhesion, which are essential for normal cellular function and tissue development.
SPIRE2 has been identified as a potential drug target and biomarker for several reasons. First, it is highly expressed in various tissues, including blood vessels, which makes it an attractive target for drug developers. Second, SPIRE2 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. Finally, SPIRE2 has been shown to be a good predictor of drug response in cancer patients, which could make it an useful biomarker for personalized medicine.
SPIRE2 functions as a nucleation factor, which means it helps to form the actin filaments that give shape to cytoskeletal structures. It is essential for the formation of tight junctions, which are the barriers that keep cells in touch and help to regulate the flow of nutrients and waste products into and out of cells. It is also involved in the regulation of cell division and the development of tissues, including blood vessels.
SPIRE2 has been shown to be involved in several cellular processes that are important for normal development and function. For example, it has been shown to be involved in the regulation of cell proliferation and differentiation, as well as in the formation of blood vessels. It has also been shown to play a role in the regulation of ion and water transport, as well as in the regulation of pain perception.
SPIRE2 has been identified as a potential drug target by several researchers because of its involvement in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that high levels of SPIRE2 are associated with poor prognosis in patients with pancreatic cancer, and that inhibiting SPIRE2 activity may be an effective way to treat this disease.
SPIRE2 has also been shown to be involved in the regulation of pain perception, which could make it an attractive target for pain medications. For example, studies have shown that SPIRE2 is involved in the regulation of pain sensitivity, and that inhibiting SPIRE2 activity may be an effective way to treat chronic pain.
In addition to its potential as a drug target, SPIRE2 has also been identified as a potential biomarker for several diseases. For example, studies have shown that SPIRE2 is expressed in the blood vessels of patients with cancer, and that its levels are associated with the development of cancer. This suggests that SPIRE2 may be a useful biomarker for cancer diagnosis and monitoring.
SPIRE2 has also been shown to be involved in the regulation of cell division and the development of tissues, which could make it an attractive target for drugs that aim to regulate these processes. For example, inhibiting SPIRE2 activity may be an effective way to treat tissue fibrosis, which is a common complication in many diseases.
In conclusion, SPIRE2 is a protein that plays a crucial role in the development and maintenance of tissues and organs, including blood vessels, neurons, and heart muscle. It is a key regulator of actin dynamics and cell-cell adhesion, and has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of SPIRE2 in these processes and to develop effective treatments.
Protein Name: Spire Type Actin Nucleation Factor 2
Functions: Acts as an actin nucleation factor, remains associated with the slow-growing pointed end of the new filament (PubMed:21620703). Involved in intracellular vesicle transport along actin fibers, providing a novel link between actin cytoskeleton dynamics and intracellular transport (By similarity). Required for asymmetric spindle positioning and asymmetric cell division during meiosis (PubMed:21620703). Required for normal formation of the cleavage furrow and for polar body extrusion during female germ cell meiosis (PubMed:21620703). Also acts in the nucleus: together with SPIRE1 and SPIRE2, promotes assembly of nuclear actin filaments in response to DNA damage in order to facilitate movement of chromatin and repair factors after DNA damage (PubMed:26287480)
More Common Targets
Spliceosomal complex | Spliceosome C complex | Spliceosome Complex | Splicing factor 3A protein complex | Splicing factor 3B protein complex | SPN | SPNS1 | SPNS2 | SPNS3 | SPO11 | SPOCD1 | SPOCK1 | SPOCK2 | SPOCK3 | SPON1 | SPON2 | SPOP | SPOPL | SPOUT1 | SPP1 | SPP2 | SPPL2A | SPPL2B | SPPL2C | SPPL3 | SPR | SPRED1 | SPRED2 | SPRED3 | SPRING1 | SPRN | SPRNP1 | SPRR1A | SPRR1B | SPRR2A | SPRR2B | SPRR2C | SPRR2D | SPRR2E | SPRR2F | SPRR2G | SPRR3 | SPRR4 | SPRTN | SPRY1 | SPRY2 | SPRY3 | SPRY4 | SPRY4-AS1 | SPRY4-IT1 | SPRYD3 | SPRYD4 | SPRYD7 | SPSB1 | SPSB2 | SPSB3 | SPSB4 | SPTA1 | SPTAN1 | SPTB | SPTBN1 | SPTBN2 | SPTBN4 | SPTBN5 | SPTLC1 | SPTLC1P1 | SPTLC2 | SPTLC3 | SPTSSA | SPTSSB | SPTY2D1 | SPX | SPZ1 | SQLE | SQOR | SQSTM1 | SRA1 | SRARP | SRBD1 | SRC | SRCAP | SRCIN1 | SRD5A1 | SRD5A1P1 | SRD5A2 | SRD5A3 | SRD5A3-AS1 | SREBF1 | SREBF2 | SREBF2-AS1 | SREK1 | SREK1IP1 | SRF | SRFBP1 | SRGAP1 | SRGAP2 | SRGAP2B | SRGAP2C | SRGAP2D | SRGAP3